# Document made available under the **Patent Cooperation Treaty (PCT)**

International application number: PCT/CA05/000068

International filing date:

21 January 2005 (21.01.2005)

Document type:

Certified copy of priority document

Document details:

Country/Office: US

Number:

60/537,882

Filing date:

22 January 2004 (22.01.2004)

Date of receipt at the International Bureau: 30 March 2005 (30.03.2005)

Remark:

Priority document submitted or transmitted to the International Bureau in

compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



FA 1278393

## THIS INTURBOSINABLE OF THE OWN

TO ALL TO WHOM THESE: PRESENTS SHALL, COMES

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 01, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/537,882

FILING DATE: January 22, 2004

By Authority of the

COMMISSIONER OF PATENTS AND TRADEMARKS

P. SWAIN

**Certifying Officer** 

U.9. Potent and Transmit Office U.S. DEPARTMENT OF COMMERCE
U.9. Potent and Transmit Office; U.S. DEPARTMENT OF COMMERCE
PROVISIONAL APPLICATION FOR PATENT COVER SHEET
This is a request for fling a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express that Label No.

INVENTOR(S)							
Given Name (first and middle (if any))	de (if anyl) Family Name or Sumane			Residence (City and either State or Foreign Country)			
Juan C.	Scalano			Oltawa, Ontorio, Canada			
Additional inventors are being named on the							
TITLE OF THE INVENTION (500 characters max)							
THERMALLY MODULATED ANTIOXIDANTS							
Direct all correspondence to:  Consumer Number:  02048							
Firm or Individual Name							
Address							
Adaress			<del></del>	<u></u>			
City		State		Zip			
Country		Teluphone		Fax			
ENCLOSED APPLICATION PARTS (check all that apply)							
Specification Number of Pages 43 CD(s), Number							
Onswing(s) Number of Sheets	3		Other (specify)				
Application Data Sheet See 37 CFR 1.78  METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PAYENT							
Applicant claims small entity status. See 37 CFR 1.27.  FILING FEE Amount (5)							
A check or money order is enclosed to cover the filling fees.							
The Director is herby authorized to charge filing fees or credit any overpayment to Depast Account Number:					160.00		
Payment by credit card. Form PTO-2038 is attached.							
The invention was made by an agency of the United States Government or under a contract with on agency of the United States Government.  No.  Yos, the name of the U.S. Government agency and the Government contract number are:							
Ruspectfutly submitted	[Page 1	."			2/04		
SIGNATURE REGISTRATION NO. 28,584							
TYPED OF PRINTED NAME Edwin J. 5219 Docket Number: 57 128							

TELEPHONE (613) 237-6900

TELEPHONE [613] 237-6900

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to better or notion a behinding by the pushes which is to Grant to compare, including to process) an application. Considerably 19 governed by 33 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 nears to compare, including generating for properties, and complete generated to precise the USPTO. Time will vary departuring upon fits behinding the complete obstained and the unique state of the Chief Information Order, U.S. Patent and Tractement Office. U.S. Department of Commerce, P.O. 801 160. Assumpts, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: that Stop Provisional Application, Commissioner for Patents, P.O., Box 1450, Alexandria, VA 22313-1450.

if you need assistance in completing the form, out 1-800-PTO-9199 and select option 2.

*Nome (Римутура)* 

Edwin J. Gale

PTO/38/17 (10-0)  Approved for use manigh 07/31/2008. ONB 0651-003/  U.S. Palonil and Trademark Office: U.S. DEPARTMENT OF COMMERCE  U.S. Palonil and Trademark Office: U.S. DEPARTMENT OF COMMERCE  Under the Paperwork Reduction and of 1995, no persons are manifested to a collection of information unless it daplags a virial OMS continual supple.								
			Complete if Known					
FEE TRANSMITTA	<b>-</b>	Application Number						
for FY 2004		Filing Date						
Effective 10701/2003, Parent fees are subject to ennual revision.		First Named Inventor			ılor	SCAIANO, Juan C.	<del></del>	
		Examiner Name						
Applicant daims small emity status. See 37 CFR 1.27		Art Unit						
TOTAL AMOUNT OF PAYMENT (\$) 160.00		Attorney Dockel No. 57			o.	57128		
METHOD OF PAYMENT (check ell that apply)	FEE CALCULATION (continued)							
Check Credit card Maney Other None	3. ADDITIONAL FEES							
Deposit Account:	Large Entity Small Entity							
Octobril Account	Fee	Foo Foo Peo Fee Description					Fee Poid_	
Number Deposit	1051	130	2051	• • •	graans	rga - tale filing fae or outh	CES LUID	
Account	1052	50	2052	25	cases :	rge - Lale provisions: filing fee or theet		
The Ofrector is authorized to: (check as that apply)	1053		1053	130	Non-E	nglish apacification		
Charge fee(s) bidicated below Crodit any overpayments	1812	-,	1812 2			g a request for ox parts reexamination	<del>  </del>	
Charge any additional foc(s) or any underpayment of fee(s)  Charge fee(s) indicated below, except for the filing fee			ı	,		sting publication of SIR prior to ter action		
to the above-identified deposit secount.	1805	1,840	1809	1,840*	Reque	sting publication of SIR after ner ection		
FEE CALCULATION	1251 1252	110	2251			dan for repty within first month		
1. BASIC FILING FEE			2252			iton for reply within second month	<b>  </b>	
Large Entity Small Bruity Pag Fee Fee Fee Fee Conscinition Fee Paid	1253 1254	950 1,460	2253 2254			ion for reply within third month	<del></del>	
Code (5) Code (6) 1001 770 2001 355 Unity filing fee	1255	-	2255			aion for reply whithin fourth month alon for reply whithin fifth month	<del>  </del>	
1002 340 2002 170 Dosign Wing fee	1401	330	2401			of Appeal		
1003 530 2003 265 Plant filing fee	1402	330	2402			priof in support of so appeal		
1004 770 2004 385 Reissus Ging Ice 160 00	1403	290	2403			st for oral hearing		
Total de l'aviant de l'ad. Co	1457	1,510	1451			n to institute a public usa processing		
SUBTOTAL (1) (S) 160.00		1.330	2453			eldabiovaru - evivon el r tampinantima - unimentima	<del>                                     </del>	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501		2501			sana taa (or taisana)		
Total Claims -20** X below Fee Paid	1502	480	2502	240	Design	iezna lee		
tridepondent -3** = X	1503 1460	640 .130	2503			sus fee		
Multiple Dependent	1807	50	1807			rs to the Commissioner Ising fee under 37 CFR 1.17(q)		
Large Entity   Smell Entity Fee Fee Fee Pre Description	1808	180	1808			island of Information Disclosure Stml	<del>  </del>	
Code (5) Code (\$)	8021	40	8021	4.5	Record	ino mech matern pesignament por		
1207 18 2202 9 Claims in oxcess of 20 1201 80 2201 43 Independent claims in excess of 3	1809	770	2809	385 F	Filing a	y (ilmes number of properties) submission after tines rejection	<b></b>	
1203 290 2203 145 Multiple dependent district, if not paid	1810	770	2810	(	(37 C.F.	R 1.129(a))		
1204 86 2204 43 "Reissue Independent claims				•	لازديهيدة	ಶ ಪರೆಯವಾಜೆ invention to be ed (37 CFR 1.129(b))		
over original patent 1205 18 2205 9 ** Rejssuc claims in excess of 20	1801 1802	770 800	2801 1602			at for Continues Examination (RCE)		
and over original patent		,		900	of a da	est for expedited exemination		
		ice (sp						
"or number previously peld, If greater, For Relatives, see above Reduced by Bosic Filing For Paid SUBTOTAL (3) (\$) 0.00								
SUBMITTED BY						(Complete (# applicate(s))		

Date

WARNING: Information ob this form may become public. Credit card information should not be included on this form. Provide credit card information and sutherization on PTO-2038.

This celection of information is required by 37 CFR 1.17 and 1.27. The information is obtained to tenth by the public which is to the (and by the VSPTO to process) on application. Connormally is governed by 35 U.S.C. 122 and 37 CFR 1.14. This celection is calculate to late 12 minutes to complete, including splanting, organizing, are submitting the completed application form to the USPTO. There will very depositing upon the individual case. Any commans on the amount of lime you require to complete this form and/or suppositions for reducing this burden, should be sent up the Child information Officer, U.S. Pazent and Transmans Officer, U.S. Pazent and SEND TO: Commissioner for Parents, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND PERS OR COMPLETED FORMS TO THIS ADDRESS.

28,584

Telephone 613-237-6900

If you need assistance in comploting the form, cell 1-800-PTO-9199 and select option 2.

04-Jan-22

## THERMALLY MODULATED ANTIOXIDANTS

#### FIELD OF THE INVENTION

The present invention relates generally to compounds that function as antioxidants. In particular, the present invention pertains to methods for the modulation of antioxidant levels in selected systems.

#### BACKGROUND TO THE INVENTION

- Antioxidants, or more specifically, chain breaking antioxidants are able to stop, delay or slow down the oxidative degradation of materials. In general, the structure of antioxidants is such that it confers on these molecules two key properties: (a) they are generally good hydrogen donors, and (b) the radical produced following hydrogen transfer is unreactive toward oxygen, thus being able to stop the chain reaction

  15 responsible for autooxidations. In the case of some antioxidants the radical (b) is capable of scavenging a second chain carrier, thus leading to a 2-1 stoichiometry; such is the case for phenolic antioxidants.
- Requirement (b), i.e. lack of reactivity toward oxygen has resulted in many antioxidants
  containing O-H bonds, since the resulting oxygen centered radicals are frequently
  unreactive towards molecular oxygen.
- In the last few years a few antioxidants have been proposed that do not contain labile O-H bonds, such as Irganox HP-136<sup>TM</sup> commercialized by Ciba Speciality Chemicals.

  Related antioxidants can be reviewed, for example, in United States Patents 5,367,008 issued November 22, 1994, and United States Patent 5,428,177, issued June 27, 1995, which are incorporated herein by reference.

04-Jan-22

Thermo-oxidative degradation can simplistically be described as a two-cycle process.

Two different types of reaction work together to create organic radicals by hydrogen abstraction, and to activate molecular oxygen by reaction with the organic radicals,

resulting in formation of peroxyl radicals, which in turn act as hydrogen abstraction active species to produce peroxides and organic radicals. Peroxides themselves serve as a source of hydrogen abstraction radicals by homolytic cleavage of the peroxo O-O bond. Different classes of antioxidants exist, which are characterized as primary antioxidants, secondary antioxidants, and carbon-centered radical scavengers. Primary antioxidants mainly act as chain-breaking antioxidants, reacting rapidly with peroxyl radicals.

Secondary antioxidants react with peroxo compounds to yield non-radical, non-reactive products. Carbon-centered radical scavengers are very effective in trapping alkyl radicals, and provide powerful processing stability. Typical examples are carbon-centered radicals derived from benzofuranone derivatives.

- When using antioxidants whose action is mediated by carbon-centered radicals, suitable precursors are typically employed, which after activation yield the carbon-centered radical. Often, such precursors are designed such that the radical is formed in a process of hydrogen abstraction. This follows a hydrogen transfer process.
- There is a continuing need to develop novel antioxidant compounds and methods that enable rapid availability of antioxidant species. In particular, there is a need to develop compounds and methods that allow for modulation of antioxidant levels in a chosen system.

25

#### SUMMARY OF THE INVENTION

It is an object of the present invention, at least in preferred embodiments, to provide a compound that can be "activated" to exhibit antioxidant activities.

It is another object of the present invention, at least in preferred embodiments, to provide a method for selective modulation of antioxidant levels in a reaction mixture or other system.

- It is another object of the present invention, at least in preferred embodiments, to provide precursors of carbon-centered radicals that are 'self-activating' in response to a change in temperature.
- It is another object of the present invention, at least in preferred embodiments, to provide precursors of carbon-centered radicals that are self-activating within a predetermined range of temperature values.

It is another object of the present invention, at least in preferred embodiments, to provide precursors of carbon-centered radicals in which the self-activating process is reversible.

- The inventors have established that the mode of operation for specific types of antioxidants, involves the formation of carbon-centered radicals that do not react with oxygen. The inventors have further determined that this mode of operation is most unusual since the vast majority of carbon-centered radicals react with oxygen at rates that approach diffusion control. Following up on this observation, the inventors have discovered a wide range of compounds that have the unusual property of producing carbon centered radicals that either do not react with oxygen, or where the reactivity is greatly attenuated.
- 25 The inventors' observations have led to the identification of an entirely new class of antioxidant compounds and systems that can be manipulated according to the ambient temperature conditions. Importantly, these systems present unique opportunities to provide reaction systems in which antioxidant levels are modulated by simple temperature shifts. Such systems may include, but are not limited to, plastics, lubricants, cooling fluids, and pharmaceutical / medical applications.

15

20

25

In accordance with one particular aspect of the instant invention, there is provided a method of providing oxidation protection comprising: providing a composition to be protected against oxidation during a high temperature portion of a thermal cycle; adding an amount of a thermally activatable dormant antioxidant species to the composition; thermally cycling the composition between a low temperature portion of the thermal cycle and the high temperature portion of the thermal cycle, to reversibly dissociate the thermally activatable dormant antioxidant species into a carbon-centered radical active antioxidant species, so as to provide an increased amount of the carbon-centered radical active antioxidant species during the high temperature portion of the thermal cycle relative to the low temperature portion of the thermal cycle.

In accordance with another aspect of the instant invention, there is provided a method for modulating oxidation protection comprising: providing a composition to be protected against oxidation at a first temperature and to other than substantially be protected at a second temperature lower than the first temperature; selecting a thermally activatable dormant antioxidant species for providing an active antioxidant species at the first temperature, the thermally activatable dormant antioxidant species thermally activatable at a temperature between the first and second temperatures; including the thermally activatable dormant antioxidant species in the composition; effecting a change to the temperature of the composition from the second temperature to the first temperature, to induce some of the thermally activatable dormant antioxidant species into the active antioxidant species; and, optionally effecting a change to the temperature of the composition from the first temperature to the second temperature, to induce some of the active antioxidant species back into the thermally activatable dormant antioxidant species.

In accordance with yet another embodiment of the instant invention there is provided a chemical product including a compound selected from those of formula 1,

wherein R1 to R9 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C<sub>1</sub> -C<sub>18</sub> alkyl, branched C<sub>1</sub> -C<sub>18</sub> alkyl, linear C<sub>2</sub>-C<sub>18</sub> alkenyl, branched C<sub>2</sub>-C<sub>18</sub> alkenyl, linear C<sub>2</sub>-C<sub>18</sub> alkynyl, branched C<sub>2</sub>-C<sub>18</sub> alkynyl, C<sub>3</sub> -C<sub>8</sub> cycloalkyl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl, and C<sub>6</sub> -C<sub>20</sub> aryl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl; or of formula II,

10

wherein R1 represents an electron withdrawing group, most preferably nitrile, and R2 to R11 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C<sub>1</sub>-C<sub>18</sub> alkyl, branched C<sub>1</sub>-C<sub>18</sub> alkyl, linear C<sub>2</sub>-

 $C_{18}$  alkenyl, branched  $C_2$ - $C_{18}$  alkenyl, linear  $C_2$ - $C_{18}$  alkynyl, branched  $C_2$ - $C_{18}$  alkynyl,  $C_5$ -C<sub>8</sub> cycloalkyl optionally substituted with one or more  $C_1$ - $C_{18}$  alkyl, and  $C_6$ - $C_{20}$  aryl optionally substituted with one or more C1-C18 alkyl; or of formula III,

wherein R3 to R15 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C1 -C18 alkyl, branched C1 -C18 10 alkyl, linear C2-C18 alkenyl, branched C2-C18 alkenyl, linear C2-C18 alkynyl, branched C2-C18 alkynyl, C5 -C8 cycloalkyl optionally substituted with one or more C1-C18 alkyl, and C<sub>6</sub>-C<sub>20</sub> aryl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl;

or a compound of formula IV, 15

15

20

wherein R1 and R3 to R10 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C<sub>1</sub>-C<sub>18</sub> alkyl, branched C<sub>1</sub>-C<sub>18</sub> alkyl, linear C<sub>2</sub>-C<sub>18</sub> alkenyl, branched C<sub>2</sub>-C<sub>18</sub> alkenyl, linear C<sub>2</sub>-C<sub>18</sub> alkynyl, branched C<sub>2</sub>-C<sub>18</sub> alkynyl, C<sub>5</sub>-C<sub>8</sub> cycloalkyl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl, and C<sub>5</sub>-C<sub>20</sub> aryl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl;

the chemical dissociating into two constituent parts through breakage of a C1-C1' labile bond upon heating thereof, each part exhibiting antioxidant activity reflecting their ability to capture free radicals, the two constituent parts preferably reassociating to reform the compound upon cooling thereof.

In accordance with still another aspect of the instant invention, there is provided an improvement in a periodically thermally cycling system, the system including a composition that is subject to substantially more exidative degradation during a high temperature portion of the thermal cycle than during a low temperature portion of the thermal cycle, the improvement comprising: a chemical component forming a part of the composition, for reversibly dissociating in response to temperature changes of the

01:81pm

composition upon repeated thermal cycling between the low temperature portion of the thermal cycle and the high temperature portion of the thermal cycle, so as to provide an amount of an active antioxidant species during the high temperature portion of the thermal cycle that is substantially larger than an amount of the active antioxidant species during the low temperature portion of the thermal cycle.

In accordance with another aspect of the present invention there is provided an antioxidant precursor compound of the formula:

#### A-B

wherein A and B are the same or different, each of A and B comprise a monocyclic or multicyclic aromatic and / or heterocyclic ring system, optionally substituted at one or more positions;

and wherein A and B are connected via a labile bond, and are susceptible to disassociation through breakage of the labile bond upon exposure of said compound to a predetermined temperature shift from a lower temperature to a higher temperature, thereby to generate corresponding free radicals A and B suitable for use as antioxidants. Preferably A and B are identical. Most preferably, each of A and B are independently selected from the group consisting of the following structures, which may be substituted or unsubstituted:

20

25

15

01:32pm

15

30

wherein each aromatic or heterocyclic ring may be unsubstituted or substituted with one or more identical or different substituents.

+18132370045

Preferably the compound has a formula selected from a compound of formula I, II, III, and IV as described herein.

Preferably, the compounds A-B exclude the compound of formula (11) disclosed in United States Patent 5,367,008 or the compound of formula (10) disclosed in United States Patent 5,428,177 or the dimeric form of Irganox HP-136 (Ciba Speciality Products) or related dimeric products.

In another aspect of the present invention there is provided the use of the compound A-B as described herein as a selectively activatable antioxidant.

In another aspect of the present invention there is provided an antioxidant composition selectively transferable between:

- (a) a low temperature non-active state wherein the composition comprises a

  dimeric compound A-B substantially devoid of antioxidant properties; and
  - (b) a high temperature active state wherein the composition comprises monomeric free radicals A and B, at least one of which exhibits antioxidant properties.
- 25 More preferably the compound A-B is the compound of Formula I, II, III, IV, IA, IB, IIA, or IIIA, as described herein.

In another aspect of the present invention there is provided a method for selectively modulating a concentration of antioxidant molecules in a reaction mixture or target environment, the method comprising the steps of:

04-Jan-22

T-279 P.012

- (a) providing a composition comprising the compound A-B as described herein;
- (b) adding the composition to the reaction mixture or target environment;
- (c) adjusting the temperature of the reaction mixture or target environment so as to modulate the concentration of antioxidant molecules in accordance with the degree of association or disassociation of A and B. 5

In a preferred aspect of the present invention there is provided a compound of formula IA, IB, IIA or IIIA as described herein.

10

15

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the absorption spectra of the monomer-radical obtained by thermal dissociation of compound IB at different temperatures;

Figure 2 provides a flow diagram of a method of providing oxidation protection according to an embodiment of the instant invention; and,

Figure 3 provides a flow diagram of a method of providing oxidation protection 20 according to another embodiment of the instant invention.

Figure 4 provides a flow diagram of a method for selectively modulating a concentration of antioxidant molecules in a reaction mixture or target environment in accordance with one embodiment of the invention.

25

30

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The following description is presented to enable a person skilled in the art to make and use the invention, and is provided in the context of a particular application and its requirements. Various modifications to the disclosed embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be

applied to other embodiments and applications without departing from the spirit and the scope of the invention. Thus, the present invention is not intended to be limited to the embodiments disclosed, but is to be accorded the widest scope consistent with the principles and features disclosed herein.

- Definition of "dimer" and "monomer" It is to be understood that throughout the description and in the claims that follow, the term "dimer" refers to compounds comprising two major moieties connected via a covalent labile bond. Each dimer may dissociate via breakage of the labile bond to form two monomeric free radicals, each comprising one of the major moieties of the dimer. At least in preferred embodiments, the term may also refer to a "head-to-head dimer". It will further be understood that the term 'dimer' preferably, but not necessarily, refers to compounds wherein the two major moieties are identical. Four specific and non-limiting examples of preferred "head-to-head dimers" comprising identical major moieties are the "head-to-head dimers" of formula I, formula III and formula IV described herein.
- 15 Definition of "thermally modulated antioxidant" The expression "thermally modulated antioxidant" is intended to encompass both dimeric (associated) and monomeric (dissociated) states of the antioxidant compounds of the present invention. For example, in selected embodiments such thermally modulated antioxidant compounds may take the form of "thermally activatable dormant antioxidant" species at lower temperatures, and yet at higher temperatures undergo dissociation to form "carbon-centered radical antioxidant" species. In this way, the thermally modulated antioxidants of the present invention can undergo a transition (preferably a reversible transition) between active radical and inactive non-radical states.
- 25 In principle, stable or persistent free radicals can act as antioxidants, i.e., a stable free radical that is either capable of trapping carbon centered or peroxyl radicals can act as an antioxidant, since such trapping will lead to a disruption of the oxidation chain. In fact, stable radicals or their precursors (HALS) are well established polymer additives.

The present invention pertains, at least in preferred embodiments, to compounds that are not themselves good antioxidants, since they are neither free radicals, nor do they have any labile hydrogen atoms. Because of their very low bond dissociation energy (normal C-C bond energies are much higher, typically 80-90 kcal/mol) these compounds 5 dissociate at moderately high temperatures producing a large concentration of free radicals that are themselves capable of scavenging the radicals that mediate the oxidative degradation of materials. These compounds can be regarded as "dormant" antioxidants. Their antioxidant activities are activated by heating. Some examples of the compounds of the present invention produce a low radical concentration, for example at 40 °C, but 10 the radical concentration is greatly enhanced at for example 100°C or higher. It is possible to achieve large concentrations of antioxidant radicals, with 10 percent or more of the dimeric compound being dissociated into active antioxidant (monomeric) form.

An important preferred characteristic of the compounds of the present invention is the 15 reversibility of the dimer to monomer transition. Thus, if the samples containing the compounds are cooled after a period of heating, the dimeric compound may reform and again exhibit dormancy in terms of antioxidant properties. Most preferably, the compounds of the present invention can be subjected to multiple cycles between inactive 20 (dimeric) and active antioxidant (monomeric) forms.

The present invention penains to a wide range of compounds each comprising a labile C-C bond. The nature of the moieties adjacent the labile bond effectively determines the bond dissociation energy (DBE) of the labile bond. Therefore, the present invention pertains to a range of compounds with a range of BDE values, such that each compound dissociates into corresponding monomer radicals at a different predetermined temperature. In this way, a compound of the invention can be selected and tailored to a specific process or use in accordance with its expected dissociation temperature or temperature range.

15

According to selected embodiments of the present invention, 'head-to-head' dimeric compounds are utilized as thermally activatable domain antioxidants. Presented below are some non-limiting examples of preferred head-to-head dimeric compounds that are encompassed within the scope of the instant invention. A first non-limiting example are the compounds of formula 1,

Preferred compounds of formula I are those wherein R1 to R9 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear  $C_1$ - $C_{18}$  alkyl, branched  $C_1$ - $C_{18}$  alkyl, linear  $C_2$ - $C_{18}$  alkenyl, branched  $C_2$ - $C_{18}$  alkenyl, linear  $C_2$ - $C_{18}$  alkynyl, branched  $C_2$ - $C_{18}$  alkynyl,  $C_5$ - $C_8$  cycloalkyl, and  $C_6$ - $C_{20}$  aryl. Further preferred compounds of formula I are those wherein the  $C_5$ - $C_8$  cycloalkyl groups carry  $C_1$ - $C_{18}$  alkyl groups as substituents. Further preferred compounds of formula I are those wherein the  $C_6$ - $C_{20}$  aryl groups carry  $C_1$ - $C_{18}$  alkyl groups as substituents.

A second non-limiting example are the compounds of formula II,

+16132970045

Preferred compounds of formula II are those wherein R1 represents an electron withdrawing group, most preferably nitrile, and R2 to R11 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C1 -C18 alkyl, branched C1 -C18 alkyl, linear C2-C18 alkenyl, branched C2-C18 alkenyl, linear C2-C18 alkynyl, branched C2-C18 alkynyl, C5-C8 cycloalkyl, and C6-C20 ary). Further preferred compounds of formula II are those wherein the C5 -C8 cycloalkyl groups carry C1 -C18 alkyl groups as substituents. Further preferred compounds of formula I) are those wherein the C<sub>6</sub>-C<sub>20</sub> aryl groups carry C<sub>1</sub>-C<sub>18</sub> alkyl groups as substituents. 10

A third non-limiting example are the compounds of formula III:

Preferred compounds of formula III are those wherein R3 to R15 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear  $C_1$  - $C_{18}$  alkyl, branched  $C_1$  - $C_{18}$  alkyl, linear  $C_2$ - $C_{18}$  alkenyl, branched  $C_2$ - $C_{18}$  alkenyl, linear  $C_2$ - $C_{18}$  alkynyl, branched  $C_2$ - $C_{18}$  alkynyl,  $C_5$  - $C_8$  cycloalkyl optionally substituted with one or more  $C_1$ - $C_{18}$  alkyl, and  $C_6$  - $C_{20}$  aryl optionally substituted with one or more  $C_1$ - $C_{18}$  alkyl.

A preferred compound of formula I, in which R1, R2, R3, R4, R5, R6, R7, R8, and R9 are hydrogen, is illustrated at formula IA, below:

25

5

10

15

20

+16132370045

Another preferred compound of formula I, in which R1, R3, R5, R6, and R9 are hydrogen, R2 and R4 are tert-butyl, R7, and R8 are methyl, is illustrated at formula IB, below:

5

10

15

A preferred compound of formula 11, in which R1 is a nitrile group, and R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are hydrogen, is illustrated at formula 11A, below:

01:33pm

A preferred compound of formula III, in which R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 and R15 are hydrogen, is illustrated at formula IIIA, below:

5 A fourth non-limiting example are the compounds of formula IV,

10

15

20

P. 020/050 F-447

Preferred compounds of formula IV are those wherein R1 and R3 to R10 are the same or different, each representing hydrogen or a substituent selected from the following nonlimiting group: linear C1-C18 alkyl, branched C1-C18 alkyl, linear C2-C18 alkenyl, branched C2-C18 alkenyl, linear C2-C18 alkynyl, branched C2-C18 alkynyl, C3-C8 cycloalkyl optionally substituted with one or more C1-C18 alkyl, and C6-C20 aryl optionally substituted with one or more C1-C18 alkyl.

One of ordinary skill in the art will envisage other similar head-to-head dimers that may be used with the methods according to embodiments of the invention.

The compounds of formula I, formula II, formula III, and formula IV are characterized by a weak C1-C1' bond. Upon heating, at least a portion of the compound of formula I, formula II, formula III, or formula IV may undergo a C-C bond cleavage reaction, to produce a pair of radical-monomers, each one of the radical-monomers being a carboncentered radical. It is the carbon-centered radicals, and not the compound itself, that principally function as an active antioxidant species. It should be noted that the antioxidant activity does not require or involve hydrogen transfer. Preferably, the radical-monomers resulting from the dissociation of the dimeric compounds are stable carbon-centered radicals with greatly attenuated reactivity toward oxygen. Without wishing to be bound by theory, it is believed that the lack of reactivity toward oxygen is attributable, at least in part, to several parameters, including but not limited to (a) benzylic resonance stabilization; (b) favorable stereoelectronic effects; (c) unpaired spin delocalization on heteroatoms and particularly oxygen; (d) electron withdrawing effects, and (e) steric effects.

Equation 1 illustrates a C-C bond cleavage reaction for a specific and non-limiting example of compound IA, which dissociates reversibly to form two carbon-centered radical-monomers IAm. Thus, heating effectively "activates" the antioxidant properties of the dimeric compounds by formation of the corresponding radical monomers. For example, when in solution, heating a sample compound to a temperature of 40°C may produce a small concentration of the radical-monomer (IAm, for instance), whereas heating to 100°C produces a significantly larger concentration of the radical monomer.

Equation 1 also illustrates the temperature dependent chemical equilibrium between the 10 dimeric compound and its corresponding radical monomer. The temperature dependent equilibrium is responsible for the fact that a radical-dimer of formula I, formula II, formula III, or formula IV is regenerated upon cooling. Advantageously, the temperature dependent equilibrium allows one to design antioxidants with tailor-made properties, such as for example having a desired minimum activity at a specific temperature. The 15 temperature dependent equilibrium may also enhance the lifetime and shelf life properties of an antioxidant according to the instant invention.

Temperature dependent absorption studies have been carried out in order to determine the bond dissociation energy (BDE) for the preferred dimers of formula IA, IB, IIA and IIIA. In particular, the monomer-radical resulting from the dissociation of each dimeric compound has characteristic absorptions in the ultraviolet and visible regions. These

10

15

20

04-Jan-22

absorptions are used to monitor the presence of the monomer-radicals in chemical equilibrium, such as for example the one illustrated at equation 1 for compound IA.

At a predetermined lower temperature the absorptions observed are different in comparison with the absorptions observed at the higher temperature ranges. However, when a sample of a compound of the invention is heated and subsequently cooled, the similar if not identical before heating and after heating. These absorbance spectrum is observations, together with other data, indicate that the dimer dissociation/formation is a reversible process.

Referring now to Figure 1, shown are the temperature dependent absorbance spectra of the monomer-radical obtained by thermal dissociation of compound IB in toluene. In particular, spectra were obtained for temperatures between 48 °C and 111 °C. From the corresponding monomer absorbance spectra, values for the BDE of the C1-C1' bond of compound IB are obtained. Data obtained from the temperature dependent study are analyzed using a simplified form of the van't Hoff equation together with Beer's law. Accordingly, the experimental absorbance A is expressed as shown in equation 2:

$$\ln A = \frac{\ln (c^2 \ell^2 [D])}{2} + \frac{\Delta S}{2R} - \frac{\Delta H}{2RT}$$
 (2)

where  $\Delta H$ , which corresponds to BDE, is obtained from the slope of an Arrhenius plot of InA vs. 1/T. Similar temperature dependent studies were carried out to determine the BDE of compounds IA, IIA and IIIA. The experimentally obtained BDE values are tabulated in Table 1.

Dimer formula	C <sub>1</sub> -C <sub>1</sub> ' BDE (kcal/mol)					
lA ·	22.2					
1B	22.8					
IIA .	26.2					
IIIA .	15.2					

Table 1: Experimentally obtained BDE values.

The data presented in Table 1 indicate that the BDE values of the compounds IA, IB, ILA, and IIIA are in a range between 15 and 26 kcal/mol, about four to five times lower than a

25

value between 80 and 90 kcal for a typical C-C bond. The data presented in Table 1 also indicate that the compounds according to the instant invention have different operating temperatures. For example, at 100°C the compound according to formula IIIA is about 670,000 times more effective than the compound according to formula IIA in producing free radicals in the active form.

The apparent stability of the compounds in Table 1 is believed to be due to the intrinsic lack of reactivity toward oxygen, which makes the back reaction to reform the dimeric compound the preferred reaction for the radical-monomer. Thus, the compounds of the present invention present the opportunity, at least in preferred embodiments, for repeated cycling between antioxidant (active) and dormant forms without significant degradation. Given the current knowledge of radical stabilities, a person of skill in the art will understand how to design materials in accordance with the instant invention that extend-the BDE range above 26 kcal/mol, or below 15 kcal/mol.

Referring now to Figure 2, shown is a simplified flow diagram of a method of providing oxidation protection according to an embodiment of the instant invention, wherein the oxidation protection occurs during the high temperature portion of a high temperature / low temperature thermal cycle. At step 100, a composition to be protected against oxidation during the high temperature portion of a thermal cycle is provided. At step 102 an amount of a thermally activatable domaint antioxidant species is added to the composition. At step 104, the composition is thermally cycled between the low temperature portion of the thermal cycle and the high temperature portion of the thermal cycle, causing dissociation of the thermally activatable domaint antioxidant species into the carbon-centered radical active antioxidant species, so as to provide an increased amount of the carbon-centered radical active antioxidant species during the high temperature portion of the thermal cycle relative to the low temperature portion of the thermal cycle. Preferably, the thermally activatable domaint antioxidant species that is added at step 102 is one of the compounds of formula 1, formula 11, formula 111, and formula IV.

15

20

25

30

Preferably, the antioxidant species that are utilized with the method according to Figure 2 remain substantially in a dormant form until thermally activated, such as for instance by thermally cycling the composition between the low temperature portion of the thermal cycle and the high temperature portion of the thermal cycle. When the composition is maintained within the high temperature portion of the thermal cycle, the active antioxidant species scavenges the radicals that mediate the oxidative degradation of materials. When the composition, and therefore the active antioxidant species, are cooled, the active antioxidant species become dormant once again, and can be reused during subsequent thermal cycles. The method according to figure 2 is suited for use with compositions that may be subject to heat-cold cycles. For instance, some exemplary and non-limiting types of compositions include some plastics, lubricants, cooling fluids, and medical / pharmaceutical applications. Preferably, the method utilizes thermally activatable dormant antioxidant species that have excellent fast response to repetitive hot-cold cycles, making the method suitable for use with systems that are subject to sudden, or "flash", changes in temperature.

Referring now to Figure 3, shown is a simplified flow diagram of a method of providing oxidation protection according to another embodiment of the instant invention. At step 110, a composition is provided that is to be protected against oxidation at a first temperature and that is to other than substantially be protected at a second temperature lower than the first temperature. At step 112, a thermally activatable dormant antioxidant species is selected for providing an active antioxidant species at the first temperature, the thermally activatable dormant antioxidant species thermally activatable at a temperature between the first and second temperatures. At step 114, the thermally activatable dormant antioxidant species is included in the composition. At step 116, a change is effected to the temperature of the composition from the second temperature to the first temperature, to induce some of the thermally activatable dormant antioxidant species into the active antioxidant species. At step 118, a change is effected to the temperature of the composition from the first temperature to the second temperature, to induce some of the active antioxidant species back into the thermally activatable dormant antioxidant species that is species. Preferably, the thermally activatable dormant antioxidant species that is

04-Jan-22

10

15

20

25

included at step 114 is one of the compounds of formula I, formula II, formula III, and formula IV.

Step 112 recites selecting a thermally activatable dormant antioxidant species for providing an active antioxidant species at the first temperature. For instance, a particular thermally activatable dormant antioxidant species having a known activation temperature or a known activation temperature range coinciding approximately with the first temperature is selected from a plurality of available thermally activatable dormant antioxidant species. Preferably, the thermally activatable dormant antioxidant species is selected from a list of available thermally activatable dormant antioxidant species, the list including data relating to activation temperature, solvent compatibility, recommended uses, etc. for a plurality of thermally activatable dormant antioxidant species. Optionally, the step of selecting includes a step of preparing a thermally activatable dormant antioxidant.

Preferably, the antioxidant species that are utilized with the method according to Figure 3 remain substantially in a dormant form until thermally activated, such as for instance by thermally cycling the composition between the low temperature portion of the thermal cycle and the high temperature portion of the thennal cycle. When the composition is maintained within the high temperature portion of the thermal cycle, the active antioxidant species scavenges the radicals that mediate the oxidative degradation of materials. When the composition, and therefore the active antioxidant species, are cooled, the active antioxidant species become substantially dormant once again, and can at least in preferred embodiments be reused during subsequent thermal cycles. The method according to figure 3 is well suited for use with compositions that may be subject to heat-cold cycles. For instance, some exemplary and non-limiting types of compositions include some plastics, lubricants, cooling fluids, and medical / pharmaceutical applications. Preferably, the method utilizes thermally activatable dormant antioxidant species that have excellent fast response to repetitive hot-cold cycles, making the method suitable for use with systems that are subject to sudden, or "flash", changes in temperature.

20

Another preferred method of the invention is illustrated with reference to Figure 4. In Figure 4 there is at step 130 provided a compound of formula A-B, wherein the compound A-B is substantially devoid of antioxidant properties, and is capable of dissociation into components A and B upon heating thereof, wherein at least one of A and B pertains to a radical exhibiting antioxidant activities. At step 132 the composition is added to a selected reaction mixture or other target environment. Moreover, at step 134 the temperature of the reaction mixture or target environment is adjusted so as to modulate the concentration of antioxidant molecules in accordance with the degree of association or disassociation of A and B. The step of adjusting may pertain to a simple temperature shift, or in alternative embodiments may pertain to several temperature steps or continual temperature changes over a period of time, thereby to modulate and vary the concentration of active antioxidant species in the system.

Two representative preparations will now be outlined in detail below, by way of specific and non-limiting examples.

## PREPARATIVE EXAMPLE 1 - Preparation of the compound according to formula IA

The dimer of formula IA was prepared by photolysis of di-tert-butyl peroxide in the presence of the corresponding monomer. A 500 mL Pyrex flask equipped with a magnetic stirring bar was used as the synthesis reactor. In the flask were placed 3-phenylisocoumaranone (10 g, 47.5 mmol), tert-butyl peroxide (100 mL, 544.3 mmol) and benzene (150 mL). The stirred solution was bubbled with nitrogen for 20 minutes and irradiated at 350 nm for 62 hours at 30°C. The irradiation dose in the UVA region of the spectrum (320 to 400 nm) was approximately 1.2 mJ/cm<sup>2</sup>. The resulting suspension was concentrated using a rotatory evaporator. The solid residue was washed with cold diethyl ether until a white solid was obtained. The white solid was then recrystallized from diethyl ether to furnish 6.2g of compound IA as a white solid (63% yield).

PREPARATIVE EXAMPLE 2 - Preparation of the compound according to formula IIIA

15

20

The dimer according to formula IIIA was obtained in a one-pot synthesis in 51% yield from the addition of 9-phenyl-9-fluorenol to stoichiometric TMS chloride and excess NaI in acctone followed by subsequent work-up of released molecular iodine with 10% sodium thiosulphate. The practically insoluble dimer was recovered from the filtration of a two-phase system of dichloromethane and aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>. The dimer is soluble in dichloromethane, and following phase separation can be recovered by evaporation of the solvent.

The thermally activated dormant antioxidants according to the instant invention are possibly used to protect materials that are subjected to heat-cold cycles, including plastics, lubricants, cooling fluids, and medical or pharmaceutical applications. In preferred embodiments of the present invention, the compounds disclosed are suitable for use in situations in which sudden flash changes in temperature occur. Potential fields of applications include oils in closed systems that are subjected to heating, oils in agricultural machines that circulate into a high temperature environment for a brief period, thermo-set resins, thermoplastic resins, and protective films subjected to heat, among others.

Optionally the thermally activated dormant antioxidants may be used in conjunction with a "common" antioxidant, such as for example an anti-oxidant that provides protection at room temperature, so as to provide anti-oxidant protection over a wide range of temperatures.

Numerous other embodiments may be envisaged without departing from the spirit and scope of the invention.

#### Claims

5

10

15

20

1. A method of providing oxidation protection, comprising:

providing a composition to be protected against oxidation during a high temperature portion of a thermal cycle;

adding an amount of a thermally activatable domain antioxidant species to the composition;

thermally cycling the composition between a low temperature portion of the thermal cycle and the high temperature portion of the thermal cycle, to reversibly dissociate the thermally activatable dormant antioxidant species into a carbon-centered radical active antioxidant species, so as to provide an increased amount of the carbon-centered radical active antioxidant species during the high temperature portion of the thermal cycle relative to the low temperature portion of the thermal cycle.

- 2. A method according to claim 1, wherein the thermally activatable dormant antioxidant species is a dimeric compound that reversibly dissociates to form two corresponding carbon-centered radical monomers, each of the two carbon-centered radical monomers being active antioxidant species.
- 3. A method according to claim 1, utilizing a compound of formula I as the thermally activatable dormant antioxidant species:

wherein R1 to R9 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear  $C_1$ - $C_{18}$  alkyl, branched  $C_1$ - $C_{18}$  alkyl, linear  $C_2$ - $C_{18}$  alkenyl, branched  $C_2$ - $C_{18}$  alkenyl, linear  $C_2$ - $C_{18}$  alkynyl,  $C_5$ - $C_8$  cycloalkyl optionally substituted with one or more  $C_1$ - $C_{18}$  alkyl, and  $C_6$ - $C_{20}$  aryl optionally substituted with one or more  $C_1$ - $C_{18}$  alkyl.

- 4. A method according to claim 3, wherein the  $C_5$  - $C_8$  cycloalkyl groups carry  $C_1$  - $C_{18}$  alkyl groups as substituents.
- 5. A method according to claim 3, wherein the  $C_6$ - $C_{20}$  aryl groups carry  $C_1$ - $C_{18}$  alkyl groups as substituents.
- 6. A method according to claim 1, utilizing a compound of formula II as the thermally
   activatable dormant antioxidant species:

wherein R1 represents an electron withdrawing group, most preferably nitrile, and R2 to R11 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C<sub>1</sub>-C<sub>18</sub> alkyl, branched C<sub>1</sub>-C<sub>18</sub> alkyl, linear C<sub>2</sub>-C<sub>18</sub> alkenyl, branched C<sub>2</sub>-C<sub>18</sub> alkynyl, C<sub>5</sub>

+16132370045

-C<sub>8</sub> cycloalkyl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl, and C<sub>6</sub> -C<sub>20</sub> aryl. optionally substituted with one or more C1-C18 alkyl

- 7. A method according to claim 6, wherein the C3 -C8 cycloalkyl groups carry C1 -C18 alkyl groups as substituents.
  - 8. A method according to claim 6, wherein the  $C_6$  - $C_{20}$  aryl groups carry  $C_1$  - $C_{18}$  alkyl groups as substituents.
- 9. A method according to claim 1, utilizing a compound of formula III as the thermally activatable dormant antioxidant species:

R14

**R10** 

Ŕ9

ŔЗ

**R15** 

20 wherein R3 to R15 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C1 -C18 alkyl, branched C1 -C18 alkyl, linear C2-C18 alkenyl, branched C2-C18 alkenyl, linear C2-C18 alkynyl, branched C2-

10

15

20

04-Jan-22

C18 alkynyl, C5 -C8 cycloalkyl optionally substituted with one or more C1-C18 alkyl, and  $C_6$  - $C_{20}$  aryl optionally substituted with one or more  $C_1$ - $C_{18}$  alkyl.

#### 10. A method of modulating oxidation protection, comprising:

providing a composition to be protected against oxidation at a first temperature and to other than substantially be protected at a second temperature lower than the first temperature;

selecting a thermally activatable dormant antioxidant species for providing an active antioxidant species at the first temperature, the thermally activatable dormant antioxidant species thermally activatable at a temperature between the first and second temperatures;

including the thermally activatable dormant antioxidant species in the composition;

effecting a change to the temperature of the composition from the second temperature to the first temperature, to induce at least some of the thermally activatable dormant antioxidant species into the active antioxidant species; and,

optionally effecting a change to the temperature of the composition from the first temperature to the second temperature, to induce some of the active antioxidant species back into the thermally activatable dormant antioxidant species.

11. A method according to claim 10, wherein the thermally activatable dormant antioxidant species is a dimeric compound that reversibly dissociates through breakage of a labile C-C hond to form two carbon-centered radicals, at least one of the two carboncentered radicals being active antioxidant species.

12. A method according to claim 10, utilizing a compound of formula I as the the thermally activatable dormant antioxidant species:

- wherein R1 to R9 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C<sub>1</sub>-C<sub>18</sub> alkyl, branched C<sub>1</sub>-C<sub>18</sub> alkyl, linear C<sub>2</sub>-C<sub>18</sub> alkenyl, branched C<sub>2</sub>-C<sub>18</sub> alkenyl, linear C<sub>2</sub>-C<sub>18</sub> alkynyl, branched C<sub>2</sub>-C<sub>18</sub> alkynyl, C<sub>5</sub>-C<sub>8</sub> cycloalkyl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl, and C<sub>6</sub>-C<sub>20</sub> aryl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl.
  - 13. A method according to claim 12, wherein the  $C_5$ - $C_8$  cycloalkyl groups carry  $C_1$ - $C_{18}$  alkyl groups as substituents.
- 14. A method according to claim 12, wherein the C<sub>6</sub>-C<sub>20</sub> aryl groups carry C<sub>1</sub>-C<sub>18</sub> alkyl groups as substituents.
  - 15. A method according to claim 10, utilizing a compound of formula ll as the thermally activatable dormant antioxidant species:

wherein R1 represents an electron withdrawing group, most preferably nitrile, and R2 to R11 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C<sub>1</sub>-C<sub>18</sub> alkyl, branched C<sub>1</sub>-C<sub>18</sub> alkyl, linear C<sub>2</sub>-C<sub>18</sub> alkenyl, branched C<sub>2</sub>-C<sub>18</sub> alkynyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl, and C<sub>6</sub>-C<sub>20</sub> aryl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl.

- 16. A method according to claim 15, wherein the C<sub>5</sub>-C<sub>8</sub> cycloalkyl groups carry C<sub>1</sub>-C<sub>18</sub> alkyl groups as substituents.
  - 17. A method according to claim 15, wherein the  $C_6$ - $C_{20}$  aryl groups carry  $C_1$ - $C_{18}$  alkyl groups as substituents.
  - 18. A method according to claim 10, utilizing a compound of formula III as the thermally activatable dormant antioxidant species:

wherein R3 to R15 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C<sub>1</sub> -C<sub>18</sub> alkyl, branched C<sub>1</sub> -C<sub>18</sub> alkyl, linear C<sub>2</sub>-C<sub>18</sub> alkenyl, branched C<sub>2</sub>-C<sub>18</sub> alkenyl, linear C<sub>2</sub>-C<sub>18</sub> alkynyl, branched C<sub>2</sub>-C<sub>18</sub> alkynyl, C<sub>5</sub> -C<sub>8</sub> cycloalkyl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl, and C<sub>6</sub> -C<sub>20</sub> aryl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl.

- 19. A method according to claim 11, wherein the thermally activatable dormant antioxidant species reversibly dissociates via a C-C bond cleavage reaction to form the two carbon-centered radicals.
  - 20. A method according to claim 19, wherein the C-C bond cleavage reaction relates to cleavage of a C-C bond having a bond dissociation energy of less than 50 kcal/mol.
- 20 21. A method according to claim 19, wherein the C-C bond cleavage reaction relates to cleavage of a C-C bond having a bond dissociation energy of less than 25 kcal/mol.

- 22. A method according to claim 10, wherein the step of including the thermally activatable dormant antioxidant species in the composition comprises adding an amount of the thermally activatable dormant antioxidant species to the composition.
- 5 23. A method according to claim 11, wherein the step of including the thermally activatable dormant antioxidant species in the composition comprises adding an amount of the thermally activatable dormant antioxidant species to the composition.
  - 24. A composition comprising a compound of formula I,

wherein R1 to R9 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C<sub>1</sub> -C<sub>18</sub> alkyl, branched C<sub>1</sub> -C<sub>18</sub>

alkyl, linear C<sub>2</sub>-C<sub>18</sub> alkenyl, branched C<sub>2</sub>-C<sub>18</sub> alkenyl, linear C<sub>2</sub>-C<sub>18</sub> alkynyl, branched C<sub>2</sub>-C<sub>18</sub> alkynyl, C<sub>5</sub> -C<sub>8</sub> cycloalkyl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl, and C<sub>6</sub> -C<sub>20</sub> aryl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl; or of formula II,

01:38pm

wherein R1 represents an electron withdrawing group, most preferably nitrile, and R2 to R11 are the same or different, each representing a substituent selected from the following non-limiting group: linear C<sub>1</sub>-C<sub>18</sub> alkyl, branched C<sub>1</sub>-C<sub>18</sub> alkyl, linear C<sub>2</sub>-C<sub>18</sub> alkenyl, branched C<sub>2</sub>-C<sub>18</sub> alkenyl, linear C<sub>2</sub>-C<sub>18</sub> alkynyl, branched C<sub>2</sub>-C<sub>18</sub> alkynyl, C<sub>5</sub>-C<sub>5</sub> cycloalkyl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl, and C<sub>6</sub>-C<sub>20</sub> aryl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl; or of formula III,

10

wherein R3 to R15 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear  $C_1$ - $C_{18}$  alkyl, branched  $C_1$ - $C_{18}$  alkyl, linear  $C_2$ - $C_{18}$  alkenyl, branched  $C_2$ - $C_{18}$  alkenyl, linear  $C_2$ - $C_{18}$  alkynyl,  $C_3$ - $C_8$  cycloalkyl optionally substituted with one or more  $C_1$ - $C_{18}$  alkyl, and  $C_6$ - $C_{20}$  aryl optionally substituted with one or more  $C_1$ - $C_{18}$  alkyl,

or of formula IV:

10

15

wherein R1 and R3 to R10 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C<sub>1</sub>-C<sub>18</sub> alkyl, branched C<sub>1</sub>-C<sub>18</sub> alkyl, linear C<sub>2</sub>-C<sub>18</sub> alkenyl, branched C<sub>2</sub>-C<sub>18</sub> alkenyl, linear C<sub>2</sub>-C<sub>18</sub> alkynyl, branched C<sub>2</sub>-C<sub>18</sub> alkynyl, C<sub>5</sub>-C<sub>8</sub> cycloalkyl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl, and C<sub>6</sub>-C<sub>20</sub> aryl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl;

From-KIRBY EADES GALE BAKER

the chemical dissociating into two constituent parts through breakage of a C<sub>1</sub>-C<sub>1</sub>' labile bond through heating thereof, each part exhibiting antioxidant activity, the two constituent parts preferably reassociating to reform the compound upon cooling thereof.

25. A periodically thermally cycling system, including a composition that is subject to substantially more oxidative degradation during a high temperature portion of the thermal cycle than during a low temperature portion of the thermal cycle, the system comprising:

a compound, capable of reversible dissociation in response to temperature changes of the composition upon repeated thermal cycling between the low temperature portion of the thermal cycle and the high temperature portion of the thermal cycle, so as to provide an amount of an active antioxidant species during the high temperature portion of the thermal cycle that is substantially larger than an amount of the active antioxidant species provided during the low temperature portion of the thermal cycle.

- 15 26. The system according to claim 25, wherein the compound is a thermally activatable dormant antioxidant species.
  - 27. The system according to claim 25, wherein the compound is a dimeric compound that reversibly dissociates to form two carbon-centered radicals, each of the two carbon-
- 20 centered radicals being active antioxidant species.

10

28. The system according to claim 25, wherein the compound is selected from those of formula I:

wherein R1 to R9 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear  $C_1$  - $C_{18}$  alkyl, branched  $C_1$  - $C_{18}$ alkyl, linear C2-C18 alkenyl, branched C2-C18 alkenyl, linear C2-C18 alkynyl, branched C2- $C_{18}$  alkynyl,  $C_5$  - $C_8$  cycloalkyl optionally substituted with one or more  $C_1$ - $C_{18}$  alkyl, and  $C_{\rm 6}$  -C  $_{\rm 20}$  aryl optionally substituted with one or more  $C_{\rm 1}\text{-}C_{\rm 18}$  alkyl.

29. The system according to claim 25, wherein the compound is selected from those of formula II:

- wherein R1 represents an electron withdrawing group, most preferably nitrile, and R2 to R11 are the same or different, each representing a substituent selected from the following non-limiting group: linear C<sub>1</sub> -C<sub>18</sub> alkyl, branched C<sub>1</sub> -C<sub>18</sub> alkyl, linear C<sub>2</sub>-C<sub>18</sub> alkenyl, branched C<sub>2</sub>-C<sub>18</sub> alkenyl, linear C<sub>2</sub>-C<sub>18</sub> alkynyl, branched C<sub>2</sub>-C<sub>18</sub> alkynyl, C<sub>5</sub> -C<sub>8</sub> cycloalkyl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl, and C<sub>6</sub> -C<sub>20</sub> aryl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl.
  - 30. The system according to claim 25, wherein the compound is selected from those of formula III:

10

wherein R3 to R15 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C1 -C18 alkyl, branched C1 -C18 alkyl, linear C2-C18 alkenyl, branched C2-C18 alkenyl, linear C2-C18 alkynyl, branched C2-C<sub>18</sub> alkynyl, C<sub>5</sub> -C<sub>8</sub> cycloalkyl optionally substituted with one or more C<sub>1</sub>-C<sub>18</sub> alkyl, and C6 -C20 aryl optionally substituted with one or more C1-C18 alkyl.

31. The system according to claim 25, wherein the compound is selected from those of formula IV as described herein, wherein R1 and R3 to R10 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C1 -C18 alkyl, branched C1 -C18 alkyl, linear C2-C18 alkenyl, branched C2-C18 alkenyl, linear C2-C18 alkynyl, branched C2-C18 alkynyl, C5 -C8 cycloalkyl optionally substituted with one or more C1-C18 alkyl, and C6-C20 aryl optionally substituted with one or more C1-C18 alkyl.

20

15

32. The method according to claim 1 or claim 10, utilizing a compound selected from those of formula IV:

10

15

20

25

wherein R1 and R3 to R10 are the same or different, each representing hydrogen or a substituent selected from the following non-limiting group: linear C1 -C18 alkyl, branched C1 -C18 alkyl, linear C2-C18 alkenyl, branched C2-C18 alkenyl, linear C2-C18 alkynyl, branched C2-C18 alkynyl, C5 -C8 cycloalkyl optionally substituted with one or more C1- $C_{18}$  alkyl, and  $C_6$  - $C_{20}$  aryl optionally substituted with one or more  $C_1$ - $C_{18}$  alkyl.

An antioxidant precursor compound of the formula:

A - B

wherein A and B are the same or different, each of A and B comprise a monocyclic or multicyclic aromatic and / or heterocyclic ring system, optionally substituted at one or more positions;

and wherein A and B are connected via a labile bond, and are susceptible to disassociation through breakage of the labile bond upon exposure of said compound to a predetermined temperature shift from a lower temperature to a higher temperature, thereby to generate corresponding free radicals A and B suitable for use as antioxidants.

The compound according to claim 33, wherein A and B are identical. 34.

35. The compound according to claim 33 or claim 34, wherein each of A and B are selected from the group consisting of:

5

R CN R

10

15

wherein each aromatic or heterocyclic ring may be unsubstituted or substituted with one or more substituents.

20

- 36. The antioxidant precursor compound according to claim 33, wherein the compound has a formula selected from a compound of formula I, II, III, and IV as described herein.
- 25 37. The antioxidant precursor compound according to claim 33, with the proviso that the compound is not the compound of formula (11) disclosed in United States Patent 5,367,008 or the compound of formula (10) disclosed in United States Patent 5,428,177 or the dimeric form of Irganox HP-136 (Ciba Speciality Products) or related dimeric products.

30

38. Use of a compound according to claim 33 as a selectively activatable antioxidant.

20

- 39. An antioxidant composition selectively transferable between:
- (a) a low temperature non-active state wherein the composition comprises a dimeric compound A-B substantially devoid of antioxidant properties; and
  - (b) a high temperature active state wherein the composition comprises monomeric free radicals A and B, at least one of which exhibits antioxidant properties.
- 10 40. The antioxident composition according to claim 39, wherein the compound A-B is the compound of Formula I, II, III, IV, IA, IB, IIA, or IIIA, as described herein.
  - 41. A method for selectively modulating a concentration of antioxidant molecules in a reaction mixture or target environment, the method comprising the steps of:
  - (a) providing a composition according to claim 39 or claim 40;
    - (b) adding the composition to the reaction mixture or target environment;
    - (c) adjusting the temperature of the reaction mixture or target environment so as to modulate the concentration of antioxidant molecules in accordance with the degree of association or disassociation of A and B.
    - 42. A compound of formula IA, IB, IIA or IIIA as described herein.

04-Jan-22

## **ABSTRACT**

Selected processes and systems require careful modulation of antioxidant concentrations.

The present invention provides dimeric compounds that are capable of reversible

dissociation into corresponding monomer radicals, with antioxidant properties, upon exposure to a predetermined temperature shift. Furthermore, the invention pertains to uses of these compounds, corresponding compositions comprising the compounds, and corresponding methods of modulating antioxidant activity in a defined reaction mixture or system. The compounds, compositions and methods of the present invention can be applied to a wide range of systems that require careful modulation of antioxidant concentrations. The capacity of the compounds of the present invention to switch reversibly between non-active (dimeric) and active antioxidant (monomeric) states provides significant advantages over the systems of the prior art.




Figure 1




Figure 2




Figure 3

04-Jan-22




Figure 4

## PATENT COOPERATION TREATY

## From the INTERNATIONAL BUREAU

## PCT

NOTIFICATION CONCERNING SUBMISSION OR TRANSMITTAL OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

MEE, Trevor R. Kirby Eades Gale Baker Box 3432, Station D Ottawa, Ontario K1P 6N9 CANADA

Date of mailing (day/month/year) 06 April 2005 (06.04.2005)	
Applicant's or agent's file reference 57128-PT	IMPORTANT NOTIFICATION
International application No. PCT/CA05/000068	International filing date (day/month/year) 21 January 2005 (21.01.2005)
International publication date (day/month/year)	Priority date (day/month/year) 22 January 2004 (22.01.2004)
Applicant	ERSITY OF OTTAWA et al

- 1. By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- 2. (If applicable) The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- 3. (If applicable) An asterisk (\*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as the priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances

Priority date Priority application No. Country or regional Office or PCT receiving Office 22 January 2004 (22.01.2004) 60/537,882 US 30 March 2005 (30.03.2005)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. +41 22 740 14 35

Authorized officer

Ben Ghachem Riadh

Facsimile No. +41 22 338 89 95

Telephone No. +41 22 338 8762

Form PCT/IB/304 (January 2004)